Not logged in BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance Nesic, Ksenija; Krais, John J.; Wang, Yifan; Vandenberg, Cassandra J.; Patel, Pooja; Cai, Kathy Q.; Kwan, Tanya; Lieschke, Elizabeth; Ho, Gwo-Yaw; Barker, Holly E.; Bedo, Justin; Casadei, Silvia; Farrell, Andrew; Radke, Marc; Shield-Artin, Kristy; Penington, Jocelyn S.; Geissler, Franziska; Kyran, Elizabeth; Betsch, Robert; Xu, Lijun; Zhang, Fan; Dobrovic, Alexander; Olesen, Inger; Kristeleit, Rebecca; Oza, Amit; McNeish, Iain; Ratnayake, Gayanie; Traficante, Nadia; DeFazio, Anna; Bowtell, David D. L.; Harding, Thomas C.; Lin, Kevin; Swisher, Elizabeth M.; Kondrashova, Olga; Scott, Clare L.; Johnson, Neil; Wakefield, Matthew J. Share Save
Share Save
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition Zboralski, Dirk; Osterkamp, Frank; Christensen, Esben; Bredenbeck, Anne; Schumann, Anne; Hoehne, Aileen; Schneider, Eberhard; Paschke, Matthias; Ungewiss, Jan; Haase, Christian; Robillard, Liliane; Simmons, Andrew D.; Harding, Thomas C.; Nguyen, Minh Share Save
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10 Colomban, Olivier; Swisher, Elizabeth M.; Kristeleit, Rebecca; McNeish, Iain; Shapira-Frommer, Ronnie; Goble, Sandra; Lin, Kevin K.; Maloney, Lara; Freyer, Gilles; You, Benoit Share Save
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib Loehr, Andrea; Hussain, Arif; Patnaik, Akash; Bryce, Alan H.; Castellano, Daniel; Font, Albert; Shapiro, Jeremy; Zhang, Jingsong; Sautois, Brieuc; Vogelzang, Nicholas J.; Chatta, Gurkamal; Courtney, Kevin; Harzstark, Andrea; Ricci, Francesco; Despain, Darrin; Watkins, Simon; King, Charmin; Nguyen, Minh; Simmons, Andrew D.; Chowdhury, Simon; Abida, Wassim Share Save
Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer Datta, Jashodeep; Dai, Xizi; Bianchi, Anna; Silva, Iago De Castro; Mehra, Siddharth; Garrido, Vanessa T.; Lamichhane, Purushottam; Singh, Samara P.; Zhou, Zhiqun; Dosch, Austin R.; Messaggio, Fanuel; Ban, Yuguang; Umland, Oliver; Hosein, Peter J.; Nagathihalli, Nagaraj S.; Merchant, Nipun B. Share Save
Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation Oza, A. M.; Lisyanskaya, A. S.; Fedenko, A. A.; de Melo, A. C.; Shparik, Y.; Bondarenko, I.; Colombo, N.; Lorusso, D.; Cibula, D.; Poka, R. L.; Oaknin, A.; Safra, T.; Mackowiak-Matejczyk, B.; Ma, L.; Thomas, D.; Lin, K. K.; McLachlan, K.; Goble, S.; Kristeleit, R. Share Save
Share Save
Share Save
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy Zboralski, Dirk; Hoehne, Aileen; Bredenbeck, Anne; Schumann, Anne; Nguyen, Minh; Schneider, Eberhard; Ungewiss, Jan; Paschke, Matthias; Haase, Christian; von Hacht, Jan L.; Kwan, Tanya; Lin, Kevin K.; Lenore, Jan; Harding, Thomas C.; Xiao, Jim; Simmons, Andrew D.; Mohan, Ajay-Mohan; Beindorff, Nicola; Reineke, Ulrich; Smerling, Christiane; Osterkamp, Frank Share Save
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study Loehr, Andrea; Patnaik, Akash; Campbell, David; Shapiro, Jeremy; Bryce, Alan H.; McDermott, Ray; Sautois, Brieuc; Vogelzang, Nicholas J.; Bambury, Richard M.; Voog, Eric; Zhang, Jingsong; Piulats, Josep M.; Hussain, Arif; Ryan, Charles J.; Merseburger, Axel S.; Daugaard, Gedske; Heidenreich, Axel; Fizazi, Karim; Higano, Celestia S.; Krieger, Laurence E.; Sternberg, Cora N.; Watkins, Simon P.; Despain, Darrin; Simmons, Andrew D.; Dowson, Melanie; Golsorkhi, Tony; Chowdhury, Simon; Abida, Wassim Share Save
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) Swisher, Elizabeth M.; Kwan, Tanya T.; Oza, Amit M.; Tinker, Anna, V; Ray-Coquard, Isabelle; Oaknin, Ana; Coleman, Robert L.; Aghajanian, Carol; Konecny, Gottfried E.; O'Malley, David M.; Leary, Alexandra; Provencher, Diane; Welch, Stephen; Chen, Lee-may; Hendrickson, Andrea E. Wahner; Ma, Ling; Ghatage, Prafull; Kristeleit, Rebecca S.; Dorigo, Oliver; Musafer, Ashan; Kaufmann, Scott H.; Elvin, Julia A.; Lin, Douglas, I; Chambers, Setsuko K.; Dominy, Erin; Lan-Thanh Vo; Goble, Sandra; Maloney, Lara; Giordano, Heidi; Harding, Thomas; Dobrovic, Alexander; Scott, Clare L.; Lin, Kevin K.; McNeish, Iain A. Share Save
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis Lee, Chee Khoon; Friedlander, Michael L.; Tjokrowidjaja, Angelina; Ledermann, Jonathan A.; Coleman, Robert L.; Mirza, Mansoor R.; Matulonis, Ursula A.; Pujade-Lauraine, Eric; Bloomfield, Ralph; Goble, Sandra; Wang, Ping; Glasspool, Rosalind M.; Scott, Clare L. Share Save
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer Lui, Goldie Y. L.; Shaw, Reid; Schaub, Franz X.; Stork, Isabella N.; Gurley, Kay E.; Bridgwater, Caroline; Diaz, Robert L.; Rosati, Rachele; Swan, Hallie A.; Ince, Tan A.; Harding, Thomas C.; Gadi, Vijayakrishna K.; Goff, Barbara A.; Kemp, Christopher J.; Swisher, Elizabeth M.; Grandori, Carla Share Save
Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer Kaur, Harsimar; Salles, Daniela C.; Murali, Sanjana; Hicks, Jessica L.; Minh Nguyen; Pritchard, Colin C.; De Marzo, Angelo M.; Lanchbury, Jerry S.; Trock, Bruce J.; Isaacs, William B.; Timms, Kirsten M.; Antonarakis, Emmanuel S.; Lotan, Tamara L. Share Save
Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP) Zboralski, D.; Osterkamp, F.; Simmons, A. D.; Bredenbeck, A.; Schumann, A.; Paschke, M.; Beindorff, N.; Mohan, A-M.; Nguyen, M.; Xiao, J.; Harding, T. C.; Hoehne, A.; Reineke, U.; Smerling, C. Share Save
Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2 Chowdhury, S.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A. H.; McDermott, R.; Sautois, B.; Vogelzang, N. J.; Bambury, R.; Voog, E.; Zhang, J.; Green, M.; Beltman, J.; Despain, D.; Simmons, A. D.; Watkins, S. P.; Golsorkhi, A.; Xiao, J.; Abida, W. Share Save
Share Save
LIO-1: A phase II study of lucitanib plus nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO) Concin, N.; Gonzalez Martin, A.; Vergote, I.; Pignata, S.; Harter, P.; Patel, M. R.; Gunderson, C. C.; Wride, K.; Lepley, D.; Dusek, R.; Go, J.; Hurley, S.; Cameron, T.; Hamilton, E. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}
